Rescue of chemorefractory classical Hodgkin lymphoma with nivolumab and autologous stem-cell transplantation: Real-life experience

被引：0
|
作者：
Buccheri, Valeria [1 ,2 ]
Fatobene, Giancarlo [1 ,3 ]
Santos, Fernanda M. [2 ]
Velasques, Rodrigo D. [2 ]
Bellesso, Marcelo [2 ]
Atanazio, Marcelo J. [1 ,2 ]
Rocha, Vanderson [1 ,2 ,3 ]
机构：
[1] Univ Sao Paulo, Fac Med, Hosp Clin, Div Hematol, Sao Paulo, Brazil
[2] Inst Canc Estado Sao Paulo, Hematol Div, Sao Paulo, Brazil
[3] Hosp Sirio Libanes, Div Oncol, Sao Paulo, Brazil
来源：
HEMATOLOGICAL ONCOLOGY | 2021年 / 39卷 / 01期
关键词：
RESPONSE ASSESSMENT; MULTICOHORT; FAILURE;
D O I：
10.1002/hon.2796
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：134 / 136
页数：3
相关论文
共 50 条
  • [31] Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
    Younes, Anas
    Santoro, Armando
    Shipp, Margaret
    Zinzani, Pier Luigi
    Timmerman, John M.
    Ansell, Stephen
    Armand, Philippe
    Fanale, Michelle
    Ratanatharathorn, Voravit
    Kuruvilla, John
    Cohen, Jonathon B.
    Collins, Graham
    Savage, Kerry J.
    Trneny, Marek
    Kato, Kazunobu
    Farsaci, Benedetto
    Parker, Susan M.
    Rodig, Scott
    Roemer, Margaretha G. M.
    Ligon, Azra H.
    Engert, Andreas
    LANCET ONCOLOGY, 2016, 17 (09): : 1283 - 1294
  • [32] Allogeneic Stem-Cell Transplantation for Hodgkin and non-Hodgkin Lymphoma: Single-center experience
    Atilla, E.
    Aydin, T.
    Merter, M.
    Ataca, P.
    Bozdag, S. Civriz
    Toprak, S. K.
    Yuksel, M. Kurt
    Topcuoglu, P.
    Arslan, O.
    Ozcan, M.
    Demirer, T.
    Ilhan, O.
    Akan, H.
    Beksac, M.
    Konuk, N.
    Gurman, G.
    BONE MARROW TRANSPLANTATION, 2015, 50 : 5619 - 5619
  • [33] HOW I TREAT RELAPSED CLASSICAL HODGKIN LYMPHOMA AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
    Akay, Olga Meltem
    LEUKEMIA RESEARCH, 2016, 49 : S11 - S11
  • [34] CHECKMATE 205 COHORT C: NIVOLUMAB IN PATIENTS WITH CLASSICAL HODGKIN LYMPHOMA AFTER PRIOR BRENTUXIMAB VEDOTIN AND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Zinzani, P. L.
    Engert, A.
    Younes, A.
    Santoro, A.
    Ansell, S.
    Timmerman, J.
    Collins, G.
    Armand, P.
    Savage, K. J.
    Trneny, M.
    Fanale, M.
    Kuruvilla, J.
    Cohen, J. B.
    Shipp, M.
    Rodig, S.
    Kato, K.
    Sumbul, A.
    Farsaci, B. A.
    Ratanatharathorn, V.
    HAEMATOLOGICA, 2016, 101 : 43 - 44
  • [35] Autologous stem cell transplantation in refractory or relapsed Hodgkin lymphoma
    Afonso, S.
    Carvalhais, I.
    Carneiro, A.
    Araujo, J.
    Principe, F.
    Guimaraes, J. E.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S440 - S441
  • [36] Autologous and allogeneic stem cell transplantation in Hodgkin's lymphoma
    Sureda, Anna
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 21 (05) : 943 - +
  • [37] Should rituximab be used prior to autologous stem-cell transplantation for non-Hodgkin's lymphoma?
    José Rodriguez
    Nature Clinical Practice Oncology, 2005, 2 : 74 - 75
  • [38] Outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin lymphoma patients in a centre from Turkey
    Sucak, Gulsan Turkoz
    Cakar, Merih Kizil
    Suyani, Elif
    Aki, Zeynep
    Altindal, Sermin
    Acar, Kadir
    HEMATOLOGY, 2013, 18 (05) : 269 - 276
  • [39] Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation
    Villa, D.
    Crump, M.
    Keating, A.
    Panzarella, T.
    Feng, B.
    Kuruvilla, J.
    ANNALS OF ONCOLOGY, 2013, 24 (06) : 1603 - 1609
  • [40] Relapse or refractory Hodgkin lymphoma: determining risk of relapse or progression after autologous stem-cell transplantation
    Bentolila, Gonzalo
    Pavlovsky, Astrid
    LEUKEMIA & LYMPHOMA, 2020, 61 (07) : 1548 - 1554
12345